安罗替尼在非小细胞肺癌铂类为基础的联合化疗方案中的应用

Application of antirotinib in platinum-based combination chemotherapy regimen for non-small cell lung cancer

目的:探讨安罗替尼在非小细胞肺癌(NSCLC)以铂类为基础联合化疗方案中的应用效果。方法:选取2021年6月至2022年12月于永城市人民医院就诊并治疗的NSCLC患者104例,随机分为研究组和对照组,每组各52例,对照组采用培美曲塞联合顺铂方案,研究组采用安罗替尼、培美曲塞联合顺铂方案。观察并比较治疗两个疗程后两组患者的临床疗效、血清肿瘤标志物水平、血管生成调节因子水平以及不良反应和患者生存质量情况。结果:同组相比,两组患者治疗后血清CEA、SCCA、CYFRA21-1、VEGF、MMP9平均值均低于治疗前,ES及FACT-L评分、KPS评分平均值均高于治疗前(P<0.05)。组间比较,治疗后,研究组患者客观缓解率(ORR)、疾病控制率(DCR)、ES平均水平、FACT-L评分、KPS评分平均值均高于对照组(P<0.05),血清CEA、SCCA、CYFRA21-1、VEGF、MMP9平均水平均低于对照组(P<0.05)。研究组与对照组患者出现乏力、出血、胃肠道反应、高血压、手足皮肤反应、白细胞与淋巴细胞计数减少、肝肾功能损害等不良反应的频率比较差异无统计学意义(P>0.05)。结论:安罗替尼联合培美曲塞、顺铂化疗方案能促进NSCLC的控制与缓解,改善血管生成调节因子水平,降低体内肿瘤标志物水平,提高患者生存质量,并且具有较好的应用安全性。

Objective:To investigate the application of antirotinib in platinum-based combination chemotherapy for non-small cell lung cancer(NSCLC).Methods:Methods A total of 104 patients with NSCLC who were treated in Yongcheng People's Hospital from June 2021 to December 2022 were randomly divided into study group and control group,with 52 cases in each group.The control group received pemetrexed combined with cisplatin,while the research group received anlotinib,pemetrexed combined with cisplatin.Clinical therapy,serum tumor marker levels,angiogenesis regulatory factor levels,adverse reactions and quality of life of patients were observed and compared between the two groups after two courses of treatment.Results:Group,compared two groups of patients after treatment serum CEA,SCCA,CYFRA21-1,VEGF,MMP9 averages are lower than before treatment,ES and FACT-l average score,KPS score were higher than before treatment(P<0.05).Comparison between groups,patients after treatment,the team objective response rate(ORR),disease control rates(DCR),ES average,FACT-L average score,KPS score were higher than control group(P<0.05),Serum CEA,SCCA,CYFRA21-1,VEGF,MMP9 average are lower than the control group(P<0.05).Weak group and control group patients,hemorrhage,gastrointestinal tract reaction,high blood pressure,hand,foot and skin,white blood cells and lymphocyte count drops,the frequency of the function of liver and kidney damage and other adverse reactions compared differences no statistical significance(P>0.05).Conclusion:Anlotinib combined with pemetrexed and cisplatin chemotherapy can promote the control and remission of NSCLC,improve the level of angiogenesis regulators,reduce the level of tumor markers in vivo,improve the quality of life of patients,and has good application safety.